Latest journalAll journals
In this interview, two experts in the field of acute myeloid leukaemia (AML), Jean-Baptiste Micol, University of Paris-Saclay, France, and Thomas Cluzeau, University Hospital of Nice, France, share their views and debate the current landscape of real-world data in AML research and treatment.
Latest articlesAll articles
Be the first to hear about new developments in #Oncology. Subscribe today, and don't forget to follow us on twitter… twitter.com/i/web/status/1…
Posted 03 December
Discover all of EMJ #Hematology articles in just one click! Have a read.. hubs.la/H0_G27-0 and follow us on… twitter.com/i/web/status/1…
Posted 02 December
Multiple myeloma is a condition that affects predominantly the older population. There are now various approved che… twitter.com/i/web/status/1…
Posted 01 December
Is allogeneic stem cell transplantation a good option for paroxysmal nocturnal haemoglobinuria? Find out here:… twitter.com/i/web/status/1…
Posted 30 November
Acute myeloid leukaemia (AML) is a highly heterogeneous disorder and is characterised by the proliferation of poorl… twitter.com/i/web/status/1…
Posted 29 November
Latest abstractsAll abstracts
Hepcidin, the Main Regulator of Iron Homeostasis, is a Marker of COVID-19 Severity and Mortality in a Cohort of Hospitalised Italian Patients
Hepcidin, the liver peptide hormone that regulates plasma iron concentration by blocking ferroportin function,4 is at the crossroad between iron metabolism and inflammation, being positively regulated by iron itself and proinflammatory cytokines,5 and may represent the link between iron deficiency and COVID-19 severity.